New Information on Antivirals and Breastfeeding

Good evidence indicates that oral PrEP regimens containing tenofovir are acceptable for use in HIV-negative nursing mothers. Maternal use of prophylactic vaginal tenofovir or dapivirine also does not appear to present a risk to the breastfed infant. Cabotegravir is not preferred in nursing mothers until further data become available. PEP regimens are acceptable for nursing mothers, but the risk of HIV transmission is an important consideration. Preliminary evidence indicates that remdesivir and favi-piravir for COVID-19 may be acceptable for nursing mothers. Sofosbuvir–ledipasvir might be acceptable for hepatis C during breastfeeding, but much more data are needed on direct-acting antivirals. © Lucia A. Jenkins et al., 2020; Published by Mary Ann Liebert, Inc. 2020.